Should Blood Lead Screening Recommendations Be Revised?

PEDIATRICS ◽  
1994 ◽  
Vol 93 (2) ◽  
pp. 201-204
Author(s):  
Birt Harvey

In October 1991, the Centers for Disease Control and Prevention (CDC) recommended blood lead (BPb) screening for virtually all 1-year-old children and, preferably, for all 2-year-old children as well.1 In April 1993, the US Department of Health and Human Services distributed guidelines recommending that all newborns, regardless of race or ethnicity, be screened for sickle cell anemia.2 In June 1993, the National Institutes of Health issued a consensus conference recommendation that all infants be tested for hearing impairment within the first 3 months of life, preferably before newborns leave the hospital.3 In each instance, these screening recommendations were developed because a group of experts, after identifying a child health problem within its area of interest, believed that universal screening was indicated.

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 825-825
Author(s):  
Marie Bernard

Abstract The National Institute on Aging (NIA) at the National Institutes of Health, Department of Health and Human Services, is the federally designated lead agency on aging research, and has supported significant research on aging as a life-long process. In the last five years, NIA experienced a tripling of its budget. Although much of this funding is targeted to Alzheimer’s disease (AD) and AD related dementias (ADRD) research, there was an increase in funds allocated to non-AD research in keeping with the overall growth of NIH. This symposium will provide a forum for exploration of the implications of the budget increases for the general research community. It will involve NIA’s senior staff discussing research priorities and programs supported by the Institute. A question-and-answer session will follow brief introductory remarks on current funding and future priorities and research directions of NIA.


2007 ◽  
Vol 16 (S1) ◽  
pp. 175-186 ◽  
Author(s):  
Bryce B. Reeve ◽  
Laurie B. Burke ◽  
Yen-pin Chiang ◽  
Steven B. Clauser ◽  
Lisa J. Colpe ◽  
...  

1991 ◽  
Vol 68 (3_suppl) ◽  
pp. 1137-1138 ◽  
Author(s):  
Thomas J. Young

Analysis of data for 12 areas of the Indian Health Services from the US Department of Health and Human Services yielded a rho of .61 between poverty and suicide for men and a significant rho of .65 for poverty with homicide rates. The Navajo area is an exception, raising for study questions about social disintegration. For the women, poverty was not significantly related to suicide or homicide rates, raising additional questions about social disintegration.


2018 ◽  
Vol 45 (1) ◽  
pp. 18-21
Author(s):  
Victoria Vorholt ◽  
Neal W Dickert

Clinical trials in emergency situations present unique challenges, because they involve enrolling individuals who lack capacity to consent in the context of acute illness or injury. The US Department of Health and Human Services and Food and Drug Administration regulations allowing an Exception from Informed Consent (EFIC) in these circumstances contain requirements for community consultation, public disclosure and restrictions on study risks and benefits. In this paper, we analyse an issue raised in the regulations that has received little attention or analysis but is ethically complex. This challenge is when to solicit and honour objections to EFIC trial enrolment, including from non-legally appointed representatives. We address novel questions involving whose objections should be honoured, what level of understanding is necessary for objections to be considered valid and how hard investigators should work to offer an opportunity to object. We present a set of criteria that provide conceptual and practical guidance. We argue that objections should be honoured if they undermine one of the key assumptions that allows for the permissibility of EFIC trials: that individuals would likely not object to enrolment based on their values or preferences. We then clarify the practical implications of this approach through examination of three cases of refusal in an EFIC study.


PEDIATRICS ◽  
1984 ◽  
Vol 74 (2) ◽  
pp. 318-318
Author(s):  
WILLIAM C. VAN OST

To the Editor.— Whenever discussion of the destructive psychosocial effects of chemical dependency emerges among medical professionals, a controversy invariably follows. Too often, discussion turns into debate, anger overcomes reason, and strong feelings are judged to be too emotional. A sad commentary about the majority of our profession is the abrogation of responsibility, leaving the major concern in the field of alcohol/drug abuse to the care of other health professionals.1-5 For those who require documentation of the belief, which I fully share, that chemical dependency can be successfully prevented and treated, I refer them to the recent "breakthrough" article by MacDonald6 as well as publications of the US Department of Health and Human Services.7,8


Sign in / Sign up

Export Citation Format

Share Document